A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

Last updated:
2026-07-18
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, PHASE 3, EFFICACY AND SAFETY STUDY OF TEZEPELUMAB IN 5 TO < 12 YEAR OLD CHILDREN WITH SEVERE UNCONTROLLED ASTHMA (HORIZON)

Intervention/treatment:
TEZSPIRE
Medical condition:
ASTHMA
Protocol code:
D5180C00016
Control number:
276054
Status:
Recruiting
Approved:
July 06, 2023
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT06023589
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
5 Years to 11 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA AB

Locations

Alberta

Research Site
Edmonton, Alberta, T6G 1C9
RECRUITING

Ontario

Research Site
Burlington, Ontario, L7L 6W6
RECRUITING
Research Site
Hamilton, Ontario, L8S 1G5
RECRUITING
Research Site
Windsor, Ontario, N8X 2G1
RECRUITING

Quebec

Research Site
Montreal, Quebec, H4A 3J1
RECRUITING
Did you find what you were looking for?